Actively Recruiting
Randomized Phase II Study Comparing Duvelisib or Oral Azacitidine with Standard Chemotherapy in Untreated CD30 Negative Peripheral T-Cell Lymphomas
Led by Alliance for Clinical Trials in Oncology · Updated on 2026-11-03
170
Participants Needed
96
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating treatments for peripheral T-cell lymphoma, specifically in patients whose cancer cells have less than 10% CD30 expression. This phase II trial compares the usual chemotherapy regimen, called CHOEP, with two experimental approaches one adding duvelisib and the other adding oral azacitidine CC-486. The study aims to determine if these additions improve the rate of complete remission and other important outcomes compared to the standard chemotherapy alone. Participants are randomly assigned to one of three groups. One group receives the standard chemotherapy combined with duvelisib taken orally twice daily for 21 days per cycle. The second group receives the standard chemotherapy plus CC-486 taken orally on specified days before and during treatment cycles. The third group receives standard chemotherapy alone. Each treatment cycle lasts 21 days, and patients may receive up to 6 cycles if their disease does not progress or if side effects are manageable. During the study, participants undergo regular evaluations including PETCT scans to measure remission status. After completing treatment, they are monitored at 6 weeks, then every 12 weeks for 2 years, and later every 24 weeks until 5 years after finishing treatment or until their lymphoma progresses. Researchers assess remission rates, overall response, survival, side effects, and patient-reported outcomes. This comprehensive follow-up helps understand the long-term effects and safety of the treatment regimens.
CONDITIONS
Brief Title
Testing the Addition of Duvelisib or CC-486 to the Usual Treatment for Peripheral T-Cell Lymphoma
Research Team
N
Neha Mehta-Shah, MD, MSCI
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here